1Academician, Professor Valeriy Zaporozhan,
2Professor Olexandr Tkachenko,
3Assistant Professor Andriy Rybin

Ukraine, Odessa, Odessa National Medical University;
1Rector of Odessa National Medical University;
2Head of Surgical Department №4 with oncology course;
3Surgical Department №4 with oncology course



The study was aimed to determine the platinum-resistance biomarkers in patients with ovarian cancer. The expression of ABCA1 is higher in platinum-resistant cases of ovarian cancer. The most pronounced relationship exists between the values of survivin expression, local activity of nitric oxide, the expression of glutathione dependent enzymes, the content of catecholamines in erythrocytes, and the expression of ABCA1 transporter

Keywords: ovarian cancer, platitum resistance, biomarkers


1. Epidemiology Working Group Steering Committee, Ovarian Cancer Association
Consortium Members of the EWG SC, in alphabetical order:, Doherty JA, Jensen A, Kelemen LE,
Pearce CL, Poole E, Schildkraut JM, Terry KL, Tworoger SS, Webb PM, Wentzensen N. Current
Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. J Natl Cancer Inst. 2017 Oct 1; 109(10).
2. Doherty JA, Peres LC, Wang C, Way GP, Greene CS, Schildkraut JM. Challenges and
Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. Curr Epidemiol Rep. 2017 Sep;4(3):211-220
3. Ивченко А. Л. Рак яичников: современные аспекты диагностики. Харківська хірургічна школа. 2015. 4(73): 147-51
4. Francis J, Coakley N, Elit L, Mackay H; Gynecologic Cancer Disease Site Group. Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline. Curr Oncol. 2017 Dec;24(6):e540-e546.
5. Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017 Dec;17(12):1147-1158.
6. Sonego M, Pellizzari I, Dall’Acqua A, Pivetta E, Lorenzon I, Benevol S, Bomben R,
Spessotto P, Sorio R, Gattei V, Belletti B, Schiappacassi M, Baldassarre G. Common biological
phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. Sci Rep. 2017 Aug 2;7(1):7104.
7. Slaughter K, Holman LL, Thomas EL, Gunderson CC, Lauer JK, Ding K, McMeekin DS,
Moore KM. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol. 2016 Aug;142(2):225-30.
8. Shafrir AL, Babic A, Tamimi RM, Rosner BA, Tworoger SS, Terry KL. Reproductive and
hormonal factors in relation to survival and platinum resistance among ovarian cancer cases. Br J
Cancer. 2016 Nov 22;115(11):1391-1399.
9. Ledermann J A, Raja F A, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO
Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
10. Тюляндин С. А., Моисеенко В. М. Практическая онкология. М., 2004 784 с.
11. Immunohistochemistry (IHC) Handbook Retrieved from
12. Рибін А. І., Лисенко М.А., Рисіна А.І. Особливості системи саногенеза у хворих на
рак яєчників, що резистентні до хіміотерапії препаратами платини. Збірник наукових праць Асоціації акушерів-гінекологів України. 2014. 1-2. 251-254.
13. Халафян А. А. Современные статистические методы медицинских исследований.
Монография. – М.:. 2014. 320